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Decentralized, or redistributed manufacture, is likely to be the manufac-
turing approach of choice for some cell- and gene-based therapies, in par-
ticular, personalized therapies. Such an approach will ultimately depend 
on the business model and will take into account the regulatory and sup-
ply chain factors. Advances in technology and integration of automated 
production platforms have demonstrated the potential for decentralized 
manufacturing, however there is a need to extend the scope of automa-
tion across the entire process including the cell isolation, distribution, 
tracking, administration, quality management systems and development 
of automated analytical techniques to facilitate real-time release. For de-
centralized manufacture to be successfully integrated for cell and gene 
therapy production, lessons from other accepted healthcare-associated 
models of manufacture can provide useful insights and perspectives to 
make informed decisions. Such models share similar characteristics to de-
centralized manufacture in that they are patient-specific and have a limit-
ed time-frame for administration. These existing approaches, which have 
successfully incorporated aspects of automation, can provide a blueprint 
for success and may expedite the decentralization of patient-specific cell 
and gene therapy manufacture.
u Published: Nov 10 2016
Since the industrial revolution, 
the manufacturing paradigm has 
changed from a localized, decentral-
ized means of production toward an 
increasingly centralized operation. 
Such an approach has facilitated 
cost-savings through economies of 
scale and scope. However, for cer-
tain cell and gene based therapies, in 
particular autologous products, it is 
likely we will witness a reversion to 
a redistributed, decentralized manu-
facturing approach. This is coupled 
with recent advances in technology 
that have permitted reproducible, 
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repeatable and reliable manufac-
ture of highly specialist products at 
a small scale  [1–5]. Equally import-
ant, however, are the advances in re-
al-time monitoring and quality man-
agement systems  (QMSs) which 
ensure that these small-scale manu-
facturing platforms are continuous-
ly monitored even in the absence of 
skilled human operators.
As technological progress in 
small scale manufacturing has ad-
vanced, the potential to manufac-
ture inherently unstable, personal-
ized cell and gene therapy products 
has become close to being realized. 
Rather than the large-scale manu-
facture of products with accompa-
nying well-connected shipping and 
distribution networks, the regulato-
ry, clinical and commercial require-
ments of personalized therapies will 
benefit from a redistribution of 
these facilities, decentralizing them 
towards a range of smaller manufac-
turing units able to respond in an 
agile manner by producing smaller 
batches of advanced, customer-spe-
cific products.
DEFINING REDISTRIBUTED 
MANUFACTURING
As with many newly coined terms, 
the definition and scope of “redis-
tributed manufacturing” is still flu-
id. Recent white papers and focus 
groups from leaders in the field have 
examined the scope this encom-
passes  [6,7]. Current understanding 
is that redistributed manufacturing 
will be local to the patient, flexi-
ble and reproducible whilst at the 
same time being more sustainable 
than centralized manufacturing 
due to its efficient use of resourc-
es. With distribution of manufac-
turing, particularly of advanced 
healthcare products, there is a reg-
ulatory requirement to ensure that 
the products manufactured at the 
distributed facilities are equivalent 
and meet the same specification. 
For this reason, the manufacturing 
process or system must be robust, 
resilient to external or internal chal-
lenges (such as changes in supplier 
of manufacturing equipment and 
changes in staff, respectively) and 
able to re-configure (e.g. increase 
or decrease the number of commis-
sioned manufacturing units) in or-
der to meet demand.
Blueprints for success
Whilst no ‘ideal model’ of redistrib-
uted manufacturing currently exists 
for cell and gene therapy produc-
tion, there are a number of accept-
ed models of manufacture currently 
being utilized in the market that can 
provide a useful perspective for deci-
sion making and from which lessons 
can be drawn when considering this 
approach. These include the manu-
facture of radioactive pharmaceuti-
cals for nuclear medicine, personal-
ly-titrated anti-cancer agents, total 
parenteral nutrition products and 
blood and platelet supplies. These 
operational models have many of the 
characteristics of the redistributed 
model for advanced therapeutics in 
that they are responsive to local clini-
cal requirements, personalized to the 
patient, delivered (often before full 
analytical characterization) within a 
narrow time window and, in some 
cases, require aseptic manufacture.
Whilst there are some notable 
differences between the manufac-
ture of more conventional health-
care products and cell and gene 
therapies, there are a large number 
of instructive parallels that can be 
drawn. These parallels are summa-
rized in Table 1. By examining these 
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four paradigms we can begin to 
understand the requirements that 
are necessary for a cell and gene 
therapy product or manufacturing 
solution to align with the existing 
market constraints. These otherwise 
hidden costs of adoption are likely 
to be of higher significance than 
the technical features of any single 
manufacturing solution, or the ef-
ficacy of any product, in terms of 
their effect on market penetration. 
Anything new must fit within, or 
only just outside current practice. 
If too large a change to practice in 
procurement, stock management, 
prescription, dispensing or adminis-
tration is required before a product 
or solution can be adopted then the 
change will be resisted.
For a decentralized manufactur-
ing system to succeed, the technolo-
gy must be robust and reproducible 
and there must be significant process 
and product understanding [8]. The 
relationship between the variation 
in properties of the starting materi-
al, the control strategy for manufac-
ture and the product features must 
be well understood. With the pro-
gression in manufacturing solutions 
for cell and gene therapies, as well 
as an enhanced understanding of 
their mechanism of action, there is 
renewed optimism that patient-spe-
cific therapies can be a clinical and 
commercial success.
The manufacture of cell and gene 
therapies will undoubtedly incur 
high costs for changes to infrastruc-
ture, requiring significant invest-
ment. This cost has traditionally 
been spread over large numbers of 
product units by using large central-
ized facilities but, as PET radioiso-
tope production demonstrates, high 
cost products can be manufactured 
in a distributed manner close to the 
end point of use. By manufacturing 
perishable goods (in the case of ra-
dioisotopes this means goods with 
a short half-life) locally, the risk of 
product loss due to inefficient trans-
port networks is also reduced.
It is possible, particularly for 
allogeneic cell products, that a 
combination of central and local 
preparation is suitable for optimal 
manufacturing, with an intermedi-
ate product being prepared at a cen-
tral facility and forwarded to local 
facilities for finishing as small cam-
paigns for immediate application to 
patients [9]. This has the dual advan-
tage of enlarging the transport win-
dow by shipping the intermediate 
at low temperature (allowing some 
flexibility in shipping dates due to 
its stable form) and manufacturing 
the Drug Product in its final for-
mulation on-site, similar to the way 
that technetium-99m radioisotope 
purification takes place. This also 
reduces the risk of supply chain fail-
ure as patients are not dependent 
upon the long-distance shipping 
step, but merely the local supply 
where delivery timing is more eas-
ily controlled. This solution also 
potentially offers a higher degree 
of customization at or near to the 
point of use whilst maintaining 
economies of scale for production 
of master stock (the intermediate) 
at a centralized facility [9].
EXISTING MANUFAC-
TURING & DISTRIBUTION 
SOLUTIONS
Development of successful distrib-
uted manufacturing platforms for 
cell- and tissue-based therapies has 
the potential to provide huge bene-
fits to the health of society. Realizing 
these goals will, however, require a 
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substantial improvement in available 
technology not only for manufacture 
of products, but also for analytical 
and monitoring purposes to facilitate 
real-time release. Many experimental 
approaches for scalable manufac-
turing and online and non-invasive 
monitoring demonstrate great suc-
cess in this area.
Whilst the growth of such 
well-established cellular platforms 
as Chinese Hamster Ovary (CHO) 
cells in scalable, automated bioreac-
tor systems is well established  [10], 
the scalable culture of adherent 
cells has proved more challeng-
ing  [11–14]. Adherent therapeutic 
cells such as dermal fibroblasts, 
chondrocytes or mesenchymal stem 
cells, are typically produced using 
planar technologies (flasks). By add-
ing multiple levels to each flask this 
production method has been scaled 
up to progress several allogeneic cell 
therapy products into mid- to late-
stage clinical development. This 
however limits culture area for pla-
nar culture to around of 3–5 million 
cm2 per lot, translating to total cell 
production batches of 100–400 bil-
lion cells for most adult primary cell 
types  [11,14,15]. This approach has 
been used successfully for around 
30 years and could theoretically be 
a template for how manufacturing 
of cell and gene therapy products 
could be automated [16–18]. Indeed 
such automated manufacturing ap-
proaches for adherent cell process-
ing for vaccine production have 
been used for clinical and commer-
cial success [19,20]. 
The default strategy for max-
imizing lot size in planar vessels 
is to adopt a scale-out approach, 
i.e. to increase the total surface 
area that is to be manipulated per 
unit operation and then repli-
cate production in multiple units. 
However for many clinical indica-
tions, achieving lot sizes of several 
hundred billion to trillions of cells 
will be imperative for commercial 
success; utilizing high-density bio-
reactor manufacturing platforms, 
such as stirred-tank bioreactors in 
conjunction with microcarriers, is 
likely to be the only way to accom-
plish this [21–25].
As our process and product un-
derstanding increases and we im-
prove our knowledge of the mech-
anism of action of therapeutic 
biologics, we can begin to investi-
gate methods to facilitate process 
intensification with increased con-
fidence. Centralized production 
allows for a reduction in costs in 
numerous areas (mainly the fixed 
overhead costs) by locating many 
aspects of the product development 
life-cycle centrally [9]. The decision 
to move to decentralized produc-
tion will forego this simplicity and 
requires a comprehensive economic 
assessment in each case, which will 
include a clear understanding of 
who the potential customer is and 
where they are located in the value 
chain before undertaking signifi-
cant investment decisions [9,26]. 
In order for decentralized manu-
facturing to succeed, effective proce-
dures for managing and automating 
procurement of starting materials 
and consumables, tracking of work 
in progress, release of product and 
overall administration must be pre-
pared. The burden of cost when this 
is done on a product-by-product 
basis is extremely high. By develop-
ing generic operations into a series 
of standards that can be adopted by 
new businesses at a pre-competitive 
stage of business development, this 
cost and responsibility can be re-
duced and barriers to investment in 
the field can be lowered.
CELL & GENE THERAPY INSIGHTS 
494 DOI: 10.18609/cgti.2016.014
AUTOMATION OF 
ADMINISTRATION
Automation of manufacturing pro-
cesses has the potential to enable 
adoption of decentralized manu-
facturing through smart and online 
control. It will also provide greater 
oversight through tracking and will 
aid administration of manufacture. 
If current manufacturing approaches 
employ a centrally managed QMS, 
how could we move to a distribut-
ed QMS which would require an 
alternative to traditional oversight? 
Automation of manufacture in a 
decentralized network can enable 
QMS changes to be rolled out across 
all sites via changes in operating 
software, thus ensuring mandatory 
compliance across sites. This ensures 
all sites, regardless of where they are 
located will be working to the same 
procedure all the time. This process 
could allow for QMSs to be partially 
decentralized, permitting cost-saving 
measures to co-exist with current 
regulatory requirements.
Knowledge of how the dominant 
features of manufacturing may alter 
the functionality of biological prod-
ucts is critical to any success with 
decentralization and will facilitate 
automated manufacture  [5,9]. It is 
anticipated that the adoption of au-
tomated manufacture will decrease 
variability in the quality of manufac-
tured cell products, resulting in more 
consistent clinical outcomes that ex-
hibit both reproducibility and, im-
portantly, dose-responsiveness. Poor 
understanding of the link between 
potency and product characteristics 
makes it challenging to develop a se-
ries of assays which reliably predict 
the result of a batch in vivo [27,28]. 
This situation is further complicated 
by the fact any assays of a fresh-pre-
served product must be complet-
ed rapidly as non-frozen cell-based 
products are not stable. This is not 
a problem in radiopharmacy where 
PET radioisotopes are assayed very 
rapidly as the half-life of the prod-
uct is measured in hours. However, 
biological potency tests can take days 
or even weeks to yield results which 
make “at risk” release of batches 
unavoidable.
Product release should depend 
ideally on rapid quality control test-
ing and as biological testing practic-
es advance this is likely to become 
a reality. For testing to be effective 
however, there must be a series of 
standards with which to compare to 
the product. Manufacture of stan-
dards of simple biological products 
could improve this situation dra-
matically and the nature of the stan-
dard may not necessarily require full 
replication of the product analysis. 
For example, could the therapeu-
tic potential of cells in which the 
mode of action involves release of 
lipid vesicles be assayed by com-
paring the vesicles in the batch to a 
standard and if so what would this 
standard look like? By manufactur-
ing simple, relatively stable biologi-
cal products such as liposomes to a 
prescribed protocol known to gen-
erate a batch of predictable charac-
teristics, a range of simple standards 
could be established that could be 
used as comparators.
As the product moves through 
the manufacturing and distribution 
supply chain, automated online 
tracking and monitoring will be an 
advantage. Decentralized manufac-
turing increases this challenge for 
such tracking as material movement 
is complex yet compliance must 
still be demonstrated. Cell and 
gene therapy products can usefully 
‘piggyback’ on the existing infra-
structure such as the blood product 
supply network not only to provide 
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a template for success (blood trans-
port wastage is estimated at ~2%) 
but also to minimize transport costs 
as barrier to adoption. Automated, 
online monitoring systems and full 
chain of custody recording will be an 
absolute necessity for decentralized 
manufacturing in order to comply 
with Good Distribution Practice. 
This will not only minimize the op-
portunity for loss and mix-ups, but 
will also ensure process compliance 
and aid detection of any problems 
that occurred during supply that 
may result in inadequate efficacy 
of a product unit. This final point 
could be critical for identification 
why a specific biologic did not work 
as expected in any given patient.
TRANSLATIONAL INSIGHT
With technical capability of cell 
and gene manufacturing systems 
advancing rapidly, the promise of 
large-scale, small-footprint redis-
tributed manufacturing is becom-
ing a reality. Whilst there are still 
gaps in automation of manufacture 
and supply which may not current-
ly be filled without a human opera-
tor, there are promising automated 
solutions emerging which should 
be able to fit into existing manufac-
turing platforms. Current analytical 
quality control systems are often 
limited by the rate of throughput of 
samples and many are destructive or 
sample-altering in nature. A range 
of measuring systems for cell- and 
tissue-based products are needed 
that are non-destructive and near 
real-time in measurement [27].
Shipping and automated track-
ing of cell and gene therapy prod-
ucts is still a nascent area, ripe for 
innovation and development. With 
the pressure on innovative com-
panies to reach clinical trials early 
there has been little opportunity 
for developing an understanding of 
how the product should be shipped 
and handled or how this could af-
fect cell function. Automation and 
tracking of the upstream scheduling 
and downstream production for cell 
and gene therapy products will be 
critical for managing material across 
distributed sites. Perhaps more im-
portant than this however are the 
insights into correct shipping and 
handling procedures for these bio-
logical products.
As challenging as the techno-
logical requirements are the radical 
changes that redistributed manufac-
turing will bring to the role of the 
operator. These involve a substantial 
change in the organization of la-
bour and roles for human operators, 
increasing the number of manufac-
turing staff across a network but 
lowering the level of skill required 
because of the extent to which the 
automated platform replaces expert 
knowledge. As the burden of re-
sponsibility shifts from operators to 
machines, a system is required that 
maintains regulatory compliance 
but is still similar enough to the cur-
rent QMSs to be acceptable from a 
societal standpoint.
Decentralized manufacturing has 
the potential to revolutionize the 
way we manufacture cell and gene 
therapy products. Patient needs can 
be met locally by a system which 
digitally manages and monitors 
patient and product requirements 
as part of an automated platform. 
In order to reach this state howev-
er there are a number of technical 
objectives that must be met. In 
order to create a system which is 
both flexible and replicable, signif-
icant progress in online monitoring 
and culture automation must be 
achieved. Progress in these areas is 
promising, particularly for a large 
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central facility, but providing all of 
these in a small footprint with mini-
mal staffing is currently not feasible. 
Products manufactured at each 
facility must be equivalent in quali-
ty, every time. In order to meet the 
challenge of a local distributed fa-
cility at geographically diverse loca-
tions, each distributed facility must 
meet the same rigorous specifica-
tion. Automation on the product 
manufacturing side is a component 
of this, but automation of the ad-
ministration, tracking and QMSs 
is an equally important share. 
Solutions for these already exist in 
other healthcare sectors and these 
paradigms can provide blueprints 
on which to base decision-making. 
Finally, it is important to remember 
that technical success of a manufac-
turing solution is not the sole indi-
cator for success; even the most bril-
liant products must sit close enough 
to the limitations of the current 
marketplace in order to overcome 
the invisible barriers to adoption.
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